Cantor News
Cantor’s Eric Johnston joined CNBC’s Closing Bell Overtime
Cantor’s Eric Johnston joined CNBC’s Closing Bell Overtime to discuss his #bearish outlook on equities
Take a Look at What’s in Store for Wet AMD & Related Diabetic Eye Diseases
Our next panel, “Take a Look at What’s in Store for Wet AMD & Related Diabetic Eye Diseases,” featured
The Doctors’ Viewpoint: What to Focus on in the Eye Space for 2023+
Our final panel, “The Doctors’ Viewpoint: What to Focus on in the Eye Space for 2023+,” featured
Do the Robot: A Discussion on How Leveraging Robots May Improve Surgical Outcomes
Our next panel, “Do the Robot: A Discussion on How Leveraging Robots May Improve Surgical Outcomes,”
Aesthetically Pleasing & Medically Necessary: Leading Aesthetic & Medical Dermatology Devices
Our next panel, “Aesthetically Pleasing & Medically Necessary: Leading Aesthetic & Medical Dermatology
Large TAM Takes Lead Role: Novel Tests in Specialized Markets
Our third panel, “Large TAM Takes Lead Role: Novel Tests in Specialized Markets,” featured John Aballi,
Distraction or Destruction?: What’s New/Next in the Industry
Our next panel, “Distraction or Destruction?: What’s New/Next in the Industry” featured Niquette
Where to Invest – Let’s Talk About What’s Topical in 2023+
Our next panel, “Where to Invest – Let’s Talk About What’s Topical in 2023+,” featured Dr.
Is Derm Defensive?: Commercial Successes, Current & Upcoming Launches
Thank you to all who joined Cantor’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic
Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus
Our second panel, “Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus,” featured
Cantor’s Eric Johnston joined CNBC’s Closing Bell Overtime
Cantor's Eric Johnston joined CNBC’s Closing Bell Overtime to discuss his #bearish equity view and